Filing Flows › Comparisons › CPMD vs SPRO
Cannapharmarx vs Spero Therapeutics: CPMD and SPRO compared
Cannapharmarx is the larger company: $276K of revenue in its latest quarter (Q2 2026) against $258K for Spero Therapeutics (Q1 2026). Cannapharmarx is growing faster (+19% against -96% a year earlier).
Where the money goes: CPMD and SPRO
Cannapharmarx (CPMD) · Q2 2026
Cannapharmarx, Q2 2026: revenue $276K (+19% year over year), operating margin -137.1%, net loss $1.9M, operating cash flow −$127K. The chart follows the revenue to costs, profit and cash.
Spero Therapeutics (SPRO) · Q1 2026
Spero Therapeutics, Q1 2026: revenue $258K (-96% year over year), net loss $7.2M, operating cash flow $15.9M. The chart follows the revenue to costs, profit and cash.
| Cannapharmarx (CPMD) | Spero Therapeutics (SPRO) | |
|---|---|---|
| Latest quarter | Q2 2026 | Q1 2026 |
| Revenue | $276K | $258K |
| Revenue growth, Y/Y | +19% | -96% |
| Operating margin | -137.1% | n/m |
| Net earnings | −$1.9M | −$7.2M |
| Net margin | -691.1% | — |
| Operating cash flow | −$127K | $15.9M |
Questions
Which is bigger, Cannapharmarx or Spero Therapeutics?
Cannapharmarx is the larger company: $276K of revenue in its latest quarter (Q2 2026) against $258K for Spero Therapeutics (Q1 2026).
Is Cannapharmarx or Spero Therapeutics growing faster?
Cannapharmarx is growing faster (+19% against -96% a year earlier).
More: Cannapharmarx earnings · how Cannapharmarx makes money · Spero Therapeutics earnings · how Spero Therapeutics makes money
From the companies' latest 10-Q, 10-K or earnings release (10-Q filed Aug 18, 2026; 10-Q filed May 13, 2026). Fiscal quarters can end on different dates. Not investment advice.